Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment

Summary

A Phase 2a clinical trial has integrated proteomic aging clocks to assess geroprotective interventions simultaneously. No specific drug, company, or outcome data is available from the provided title.